External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.

Publication Type:

Journal Article

Source:

International journal of radiation oncology, biology, physics, Volume 92, Issue 2, p.236-43 (2015)

Abstract:

Optimizing androgen suppression may provide better control of localized prostate cancer (PCa). Numerous trials have supported the benefit of combining androgen deprivation therapy with definitive radiation therapy in men with locally advanced or high-grade disease. Addition of abiraterone to luteinizing hormone-releasing hormone agonist (LHRHa) with radiation has not been reported. We examined the safety of this combination as well as its impact on androgen suppression.